An Open-Label Rollover Study of PBI-4050 in Subjects with Alström Syndrome - A Rollover Study of PBI-4050 in Subjects with Alström Syndrome
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of its Effects on the Inflammatory, Fibrosis,Diabetes and Obesity Biomarkers in Subjects with Alström Syndrome - Phase II Study of PBI-4050 in Subjects with Alström Syndrome
100 Clinical Results associated with ProMetic Biosciences (USA), Inc.
0 Patents (Medical) associated with ProMetic Biosciences (USA), Inc.
100 Deals associated with ProMetic Biosciences (USA), Inc.
100 Translational Medicine associated with ProMetic Biosciences (USA), Inc.